Gilead Sciences, Inc. (NASDAQ:GILD) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 11,548,612 shares, a decline of 14.0% from the January 15th total of 13,429,498 shares. Approximately 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 7,327,632 shares, the short-interest ratio is presently 1.6 days.
In related news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the sale, the director now directly owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.16% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Patriot Financial Group Insurance Agency LLC increased its position in Gilead Sciences by 646.6% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 4,069 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 3,524 shares in the last quarter. Addenda Capital Inc. increased its position in Gilead Sciences by 2.3% during the 4th quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock worth $3,735,000 after purchasing an additional 1,362 shares in the last quarter. Meeder Asset Management Inc. increased its position in Gilead Sciences by 6.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 100,070 shares of the biopharmaceutical company’s stock worth $7,726,000 after purchasing an additional 5,841 shares in the last quarter. IMA Wealth Inc. increased its position in Gilead Sciences by 31.6% during the 4th quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 1,710 shares in the last quarter. Finally, S&CO Inc. increased its position in Gilead Sciences by 5.5% during the 4th quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock worth $396,000 after purchasing an additional 330 shares in the last quarter. 80.03% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have issued reports on GILD shares. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday, November 8th. Raymond James restated a “buy” rating on shares of Gilead Sciences in a report on Thursday, November 1st. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Finally, Guggenheim started coverage on shares of Gilead Sciences in a report on Monday, December 17th. They issued a “buy” rating and a $86.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $86.85.
NASDAQ GILD opened at $67.62 on Tuesday. Gilead Sciences has a 12 month low of $60.32 and a 12 month high of $82.71. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.36 and a quick ratio of 3.29. The stock has a market cap of $87.28 billion, a PE ratio of 11.00, a P/E/G ratio of 66.65 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period last year, the company posted $1.78 EPS. On average, analysts expect that Gilead Sciences will post 6.23 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio is 37.07%.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Read More: Derivative
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.